Company attributes
Other attributes
Boston-based Zea exists to grow access to reliable medicines to inspire healthier communities.
As a plant biotechnology platform focused on identifying, producing and growing high-potency drugs, we are on a mission to unlock more molecules for more medicine than ever before possible.
To date, we have already grown 263 plant species that have the potential to treat nearly 1,000 diseases worldwide.
Our founder, Jim Wilson, is fascinated with growing things and taking a top-down approach to ensure they succeed.
Perhaps it's the farmer from a small town inside him combined with his many years as a pilot. Either way, he is always blazing a new path that not many have traversed, and even fewer have envisioned--a world where we grow our own medicine.
Zea started in the food industry, growing and selling lettuce in 2016--where teams were able to optimize a unique growing platform that could deliver a path to the predictability and unrivaled precision.
The crisis of COVID-19 gave Zea a unique opportunity to move the precision growing platform into the pharmaceuticals market.
Along with a vastly experienced science board and management team, Zea has rapidly accelerated its technology platform over the last 24 months--believing that plant biologics can transform the treatment of diseases both from a production and manufacturing point of view.
Today, Zea is able to identify, test and trial the existence of molecules and their reproduction inside plants --similar to a bioreactor. Zea has many pilot projects in the pipeline, too.
